Share
1,189 Posts.
lightbulb Created with Sketch. 723
clock Created with Sketch. 02/07/22
16:31
Share
Originally posted by Bazsa:
↑
"The strength of the data isn't the only thing they consider." "What hinders MSB is the fact that the mechanism doesn't fit (not just my thinking, also the expert panel), and MSCs are still very experimental (as opposed to a beta blocker such as carvedilol which has similar drugs of the same family that are extremely well understood and utilised)." "So sure, there's always a possibility."
Expand
Potency assays being agreed with OTAT as 'reasonable' is one of the least understood aspects of this stock - this was major news in October last year but seems to have been forgotten about - I expect MSB will be patenting this potency assay technique and all others that follow on in the cell therapy market will have to pay MSB to use the tech.
(20min delay)